miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients

Non-small-cell lung cancer (NSCLC) is the most common malignancy worldwide. Platinum-based chemotherapy is the standard of care for these patients. Recent research showed that miR-7 methylation status is a biomarker of cisplatin resistance in lung and ovarian cancer cells, which is one of the major...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Antolín, Carlos, Felguera-Selas, Laura, Pernía, Olga, Vera, Olga, Esteban, Isabel, Losantos García, Itsaso, de Castro, Javier, Rosas-Alonso, Rocío, Ibanez de Caceres, Inmaculada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686393/
https://www.ncbi.nlm.nih.gov/pubmed/31406565
http://dx.doi.org/10.1186/s13578-019-0326-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686393/
https://www.ncbi.nlm.nih.gov/pubmed/31406565
http://dx.doi.org/10.1186/s13578-019-0326-7

Ejemplares similares